Jichuan Pharmaceutical: Pudilan Anti-inflammatory Oral Liquid is authorized as a second-level protected traditional Chinese medicine variety.

Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group's Pudilan XIAOYAN oral liquid has been approved as a second-class protected Chinese medicine variety by the state, with a protection period of seven years from the date of announcement. The product is a unique dosage form with the effects of clearing heat, detoxifying, reducing swelling, and relieving sore throat, suitable for the treatment of upper respiratory tract infectious diseases, and has been included in more than thirty guidelines and consensus on diagnosis and treatment. This approval is beneficial for intellectual property protection, but will not have a significant impact on current operating performance. Sales may be affected by policies and market conditions, leading to uncertainties.